SE0102327D0 - A novel engineered superantigen for human therapy - Google Patents

A novel engineered superantigen for human therapy

Info

Publication number
SE0102327D0
SE0102327D0 SE0102327A SE0102327A SE0102327D0 SE 0102327 D0 SE0102327 D0 SE 0102327D0 SE 0102327 A SE0102327 A SE 0102327A SE 0102327 A SE0102327 A SE 0102327A SE 0102327 D0 SE0102327 D0 SE 0102327D0
Authority
SE
Sweden
Prior art keywords
superantigen
human therapy
novel engineered
engineered superantigen
novel
Prior art date
Application number
SE0102327A
Other languages
English (en)
Inventor
Goeran Forsberg
Eva Erlandsson
Per Antonsson
Bjoern Walse
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0102327A priority Critical patent/SE0102327D0/sv
Publication of SE0102327D0 publication Critical patent/SE0102327D0/sv
Priority to US09/900,766 priority patent/US7125554B2/en
Priority to JP2003508382A priority patent/JP4523773B2/ja
Priority to ES02746240.7T priority patent/ES2564041T3/es
Priority to YU101503A priority patent/RS52581B/en
Priority to CA2451847A priority patent/CA2451847C/en
Priority to UA2004010601A priority patent/UA85993C2/ru
Priority to PCT/SE2002/001188 priority patent/WO2003002143A1/en
Priority to CZ2003-3559A priority patent/CZ307180B6/cs
Priority to DK02746240.7T priority patent/DK1406657T3/en
Priority to IL15956202A priority patent/IL159562A0/xx
Priority to EP02746240.7A priority patent/EP1406657B1/en
Priority to BRPI0210568-3 priority patent/BRPI0210568B8/pt
Priority to RU2004102199/13A priority patent/RU2307837C2/ru
Priority to HU0400313A priority patent/HUP0400313A3/hu
Priority to SK1611-2003A priority patent/SK16112003A3/sk
Priority to NZ529827A priority patent/NZ529827A/en
Priority to EEP200400037A priority patent/EE05475B1/xx
Priority to KR1020037016268A priority patent/KR100961054B1/ko
Priority to CN028131045A priority patent/CN1522156B/zh
Priority to MXPA03011761A priority patent/MXPA03011761A/es
Priority to PL368048A priority patent/PL216516B1/pl
Priority to ZA2003/09150A priority patent/ZA200309150B/en
Priority to HRP20031054AA priority patent/HRP20031054B1/hr
Priority to IS7083A priority patent/IS2986B/is
Priority to BG108499A priority patent/BG66321B1/bg
Priority to NO20035773A priority patent/NO333676B1/no
Priority to IL159562A priority patent/IL159562A/en
Priority to HK04110098.6A priority patent/HK1067980A1/xx
Priority to US11/526,437 priority patent/US7615225B2/en
Priority to US12/568,579 priority patent/US20100111978A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/06—Message adaptation to terminal or network requirements
    • H04L51/063—Content adaptation, e.g. replacement of unsuitable content
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/58—Message adaptation for wireless communication

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE0102327A 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy SE0102327D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy
US09/900,766 US7125554B2 (en) 2001-06-28 2001-07-06 Engineered superantigen for human therapy
PL368048A PL216516B1 (pl) 2001-06-28 2002-06-19 Koniugat obejmujący superantygen bakteryjny i część stanowiącą przeciwciało, zastosowanie tego koniugatu i kompozycja farmaceutyczna
HU0400313A HUP0400313A3 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
EEP200400037A EE05475B1 (et) 2001-06-28 2002-06-19 Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
YU101503A RS52581B (en) 2001-06-28 2002-06-19 NEW CONSTRUCTED SUPERANTIGEN FOR HUMAN THERAPY
CA2451847A CA2451847C (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
UA2004010601A UA85993C2 (ru) 2001-06-28 2002-06-19 Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
PCT/SE2002/001188 WO2003002143A1 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
CZ2003-3559A CZ307180B6 (cs) 2001-06-28 2002-06-19 Konjugát obsahující superantigen a protilátkovou skupinu, a farmaceutický prostředek s obsahem konjugátu
DK02746240.7T DK1406657T3 (en) 2001-06-28 2002-06-19 NEW TECHNICAL MADE superantigen TO TREAT PEOPLE
IL15956202A IL159562A0 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
EP02746240.7A EP1406657B1 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
BRPI0210568-3 BRPI0210568B8 (pt) 2001-06-28 2002-06-19 conjugado, uso de um conjugado, e, composição farmacêutica
RU2004102199/13A RU2307837C2 (ru) 2001-06-28 2002-06-19 Новый биотехнологически созданный суперантиген для лечения человека
JP2003508382A JP4523773B2 (ja) 2001-06-28 2002-06-19 ヒト治療用新規組換えスーパー抗原
SK1611-2003A SK16112003A3 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
NZ529827A NZ529827A (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy
ES02746240.7T ES2564041T3 (es) 2001-06-28 2002-06-19 Un nuevo superantígeno modificado genéticamente para terapia humana
KR1020037016268A KR100961054B1 (ko) 2001-06-28 2002-06-19 암을 치료하기 위해 조작한 신규한 초항원을 포함하는 접합체, 이를 포함하는 조성물 및 이를 사용하는 방법
CN028131045A CN1522156B (zh) 2001-06-28 2002-06-19 用于人类治疗的新型工程超级抗原
MXPA03011761A MXPA03011761A (es) 2001-06-28 2002-06-19 Un nuevo superantigeno disenado para terapia humana.
ZA2003/09150A ZA200309150B (en) 2001-06-28 2003-11-25 A novel engineered superantigen for human therapy
HRP20031054AA HRP20031054B1 (hr) 2001-06-28 2003-12-17 Novo proizveden superantigen za humanu terapiju
IS7083A IS2986B (is) 2001-06-28 2003-12-18 Nýr tilbúinn fjölræsivaki til að nota við meðferð á manneskjum
BG108499A BG66321B1 (bg) 2001-06-28 2003-12-22 Генноинженерно получен конюгат за лечение на хора, който съдържа суперантиген
NO20035773A NO333676B1 (no) 2001-06-28 2003-12-22 Nytt konstruert superantigen for human terapi
IL159562A IL159562A (en) 2001-06-28 2003-12-24 Conjugate comprising a modified bacterial superantigen and an antibody moiety and use thereof in the treatment of cancer
HK04110098.6A HK1067980A1 (en) 2001-06-28 2004-12-21 A novel engineered superantigen for human therapy
US11/526,437 US7615225B2 (en) 2001-06-28 2006-11-21 Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen
US12/568,579 US20100111978A1 (en) 2001-06-28 2009-09-28 Conjugates between a variant staphylococcal enterotoxin e superantigen and a targeting antibody that binds to a cancer-associated cell surface structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy

Publications (1)

Publication Number Publication Date
SE0102327D0 true SE0102327D0 (sv) 2001-06-28

Family

ID=20284677

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy

Country Status (28)

Country Link
US (3) US7125554B2 (sv)
EP (1) EP1406657B1 (sv)
JP (1) JP4523773B2 (sv)
KR (1) KR100961054B1 (sv)
CN (1) CN1522156B (sv)
BG (1) BG66321B1 (sv)
BR (1) BRPI0210568B8 (sv)
CA (1) CA2451847C (sv)
CZ (1) CZ307180B6 (sv)
DK (1) DK1406657T3 (sv)
EE (1) EE05475B1 (sv)
ES (1) ES2564041T3 (sv)
HK (1) HK1067980A1 (sv)
HR (1) HRP20031054B1 (sv)
HU (1) HUP0400313A3 (sv)
IL (2) IL159562A0 (sv)
IS (1) IS2986B (sv)
MX (1) MXPA03011761A (sv)
NO (1) NO333676B1 (sv)
NZ (1) NZ529827A (sv)
PL (1) PL216516B1 (sv)
RS (1) RS52581B (sv)
RU (1) RU2307837C2 (sv)
SE (1) SE0102327D0 (sv)
SK (1) SK16112003A3 (sv)
UA (1) UA85993C2 (sv)
WO (1) WO2003002143A1 (sv)
ZA (1) ZA200309150B (sv)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CN1275085A (zh) * 1997-07-21 2000-11-29 法玛西雅和厄普约翰公司 靶细胞的定向细胞溶解、引起细胞溶解的试剂和组合物以及可用于制备这些试剂的化合物
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP4516914B2 (ja) * 2003-03-28 2010-08-04 一般財団法人化学及血清療法研究所 Ｓｅｂ改変体およびそれを含有する免疫異常性疾患の予防・治療用剤
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20080274133A1 (en) * 2004-11-18 2008-11-06 Avidex Ltd. Soluble Bifunctional Proteins
GB0427585D0 (en) * 2004-12-16 2005-01-19 Avidex Ltd Assay
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2846432A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
RU2707251C2 (ru) 2011-10-03 2019-11-25 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
CN103965302B (zh) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 一种重组超抗原seb突变体，其制备方法及应用
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
CA3010678A1 (en) 2016-01-10 2017-07-20 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
CN110996993B (zh) 2017-07-27 2024-05-31 Ab疫苗公司 包含源自超抗原类毒素的融合肽的免疫原性组合物
KR20220009428A (ko) 2019-05-15 2022-01-24 네오티엑스 테라퓨틱스 엘티디. 암 치료
CA3170369A1 (en) 2020-03-05 2022-04-14 Michal Shahar Methods and compositions for treating cancer with immune cells
IL301406A (en) * 2020-09-28 2023-05-01 Janssen Pharmaceuticals Inc Variant polypeptides of STAPHYLOCOCCUS AUREUS LUKA and LUKB and vaccine compositions
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6042837A (en) 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
WO1991010680A1 (en) 1990-01-17 1991-07-25 Terman David S Tumor killing effects of enterotoxins and related compounds
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
ES2078518T3 (es) 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
US5858363A (en) 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
ATE239089T1 (de) 1991-12-24 2003-05-15 Harvard College Gezielte punkt-mutagenese von dna
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
EP0832241B1 (en) 1995-06-07 2005-03-23 Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
EP0891436B1 (de) 1996-03-27 2001-11-28 Zellweger Luwa Ag Verfahren und vorrichtung zur qualitätsüberwachung von garnen
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6447777B1 (en) 1996-03-29 2002-09-10 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6774218B2 (en) 1996-12-06 2004-08-10 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
AU734597B2 (en) 1996-12-06 2001-06-21 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
WO1998024911A2 (en) 1996-12-06 1998-06-11 Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
WO2001036486A2 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
CN1275085A (zh) 1997-07-21 2000-11-29 法玛西雅和厄普约翰公司 靶细胞的定向细胞溶解、引起细胞溶解的试剂和组合物以及可用于制备这些试剂的化合物
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
EP1097212B1 (en) 1998-07-10 2008-12-24 U.S. Medical Research Institute of Infectious Diseases Anthrax vaccine
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20010046501A1 (en) 2000-03-14 2001-11-29 Johnson Howard M. Superantigen enhancement of specific immune responses
JP4283430B2 (ja) 2000-09-26 2009-06-24 株式会社カネカ エンテロトキシンの吸着材、吸着除去方法および吸着器
AU1648102A (en) 2000-12-04 2002-06-18 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
CN1369550A (zh) 2001-02-16 2002-09-18 沈阳协合集团有限公司 一种金黄色葡萄球菌的培养物及其制备方法
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
KR20050042791A (ko) * 2002-08-21 2005-05-10 메르크 파텐트 게엠베하 포도상구균 장독소 ｂ의 ｔ-세포 에피토프
US20090162315A1 (en) * 2004-06-29 2009-06-25 Terman David S Enterotoxin gene cluster (egc) superantigens to treat malignant disease
US20060005711A1 (en) 2004-07-07 2006-01-12 Andrew Olefson Replaceable filter for a vehicle air conditioning system adapted to scent air
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20070280905A1 (en) * 2006-06-01 2007-12-06 Shulin Li Prognosis and Systemic Therapy for Treating Malignancy

Also Published As

Publication number Publication date
IL159562A (en) 2010-12-30
PL216516B1 (pl) 2014-04-30
EE05475B1 (et) 2011-10-17
HK1067980A1 (en) 2005-04-22
IS7083A (is) 2003-12-18
MXPA03011761A (es) 2004-04-02
CN1522156A (zh) 2004-08-18
YU101503A (en) 2006-05-25
NO333676B1 (no) 2013-08-05
HRP20031054B1 (hr) 2016-12-30
US20100111978A1 (en) 2010-05-06
WO2003002143A1 (en) 2003-01-09
BR0210568A (pt) 2004-08-03
ZA200309150B (en) 2005-01-26
PL368048A1 (en) 2005-03-21
JP2005503362A (ja) 2005-02-03
IS2986B (is) 2017-09-15
EE200400037A (et) 2004-04-15
CZ20033559A3 (en) 2004-06-16
JP4523773B2 (ja) 2010-08-11
IL159562A0 (en) 2004-06-01
HUP0400313A3 (en) 2006-02-28
NO20035773L (no) 2004-02-27
US20030039655A1 (en) 2003-02-27
UA85993C2 (ru) 2009-03-25
HUP0400313A2 (hu) 2004-09-28
EP1406657A1 (en) 2004-04-14
KR20040015264A (ko) 2004-02-18
BRPI0210568B1 (pt) 2020-10-13
RU2307837C2 (ru) 2007-10-10
US7125554B2 (en) 2006-10-24
CA2451847C (en) 2012-10-16
BG66321B1 (bg) 2013-05-31
BRPI0210568B8 (pt) 2021-05-25
DK1406657T3 (en) 2016-03-07
KR100961054B1 (ko) 2010-06-01
CN1522156B (zh) 2012-10-10
RU2004102199A (ru) 2005-05-20
EP1406657B1 (en) 2015-12-30
HRP20031054A2 (en) 2004-04-30
SK16112003A3 (en) 2004-11-03
CZ307180B6 (cs) 2018-02-28
BG108499A (en) 2005-03-31
US7615225B2 (en) 2009-11-10
RS52581B (en) 2013-04-30
NZ529827A (en) 2005-06-24
CA2451847A1 (en) 2003-01-09
US20070082001A1 (en) 2007-04-12
ES2564041T3 (es) 2016-03-17

Similar Documents

Publication Publication Date Title
SE0102327D0 (sv) A novel engineered superantigen for human therapy
EP2371389A3 (en) FcgammaRIIB-specific antibodies and methods of use thereof
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
AU2002215935A1 (en) Novel use of short-chained carboxylic acids
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
PT1261367E (pt) Utilizacao de antagonistas da interleucina 6 para o tratamento de tumores dependentes de estrogenios
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
AU2002221908A1 (en) Novel use of protein hydrolysates
NO20031860D0 (no) Kahalaolid F
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
MY130373A (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.
AU6722498A (en) Disubstituted biphenyloxazolines
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
CY1105981T1 (el) Ενωσεις 5-πυριδυλ-1,3-αζολιου, μεθοδοι παρασκευης αυτων και χρηση αυτων
RS51793B (en) POLIMERNI conjugated HMGB1 HMGB1 VARIJANTI I BOX A BOX A
ATE490981T1 (de) Criptospezifische antikörper